Head-to-head evidence
Forimtamig vs TQB2029
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: GPRC5D x CD3 · full Multiple Myeloma pipeline
Forimtamig
Developed by Roche
NCT06055075 · Phase 1/2 · terminated
Although the record lists randomized allocation, this was a small, open-label study with no placebo or active comparator and only 21 participants. Its primary outcomes included clinical response measures and safety, but no results are posted to show whether any endpoint was met.
TQB2029
Developed by Sino Biopharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Forimtamig's landscape · TQB2029's landscape